Loading
24 upcoming events across 17 companies: 5 with a confirmed date, the rest editorial estimates that can slip by quarters. Filter by company or quarter, then download the selection as an .ics file or subscribe to the full feed.
Europe's largest oncology congress. Watch for: TROPION-Breast05, first-line ADC + IO data, late-breaking radioligand and bispecific ADC results.
SourceThe breast cancer congress. Post-neoadjuvant TNBC ADC trials (ASCENT-05, TROPION-Breast03) and sac-TMT first-line TNBC data are candidates for presentation here or at ESMO.
Haematology's main congress: CAR-T, bispecifics, menin inhibitors, BCL-2 combinations.
All-stock deal at $16.25 per share announced July 2026; the companies guided to a close in late 2026 or early 2027.
SourcePrimary completion per registry falls in 2026; timing of topline is our estimate. Would complete the ADC + IO first-line picture alongside ASCENT-04.
Topline positive 19 August 2026; hazard ratios and curves expected at a late-2026 congress (ESMO or SMR), with regulatory filings to follow.
SourceFull results presented at ASCO 2026 (primary stage III to IV endpoint not met; stage IV reduction reported). NHS England said it would wait for final results before any rollout decision; timing of a decision is not announced.
SourceNovartis announced the supplemental filing after the PSMAddition results in 2025. No action date has been disclosed; the year is our estimate.
SourceFully enrolled; event-driven OS endpoint. Sponsor has guided to a readout in 2026 or 2027. The first pivotal test of a pan-RAS inhibitor.
SourceEarly science and first-in-human data: next-generation ADC payloads, degraders, in vivo CAR-T.
SourceWhere most practice-changing phase 3 trials are first presented.
SourceGlobal first-line trial of the EGFR×HER3 bispecific ADC; timing is an estimate from enrolment start (2025).
Registry estimated primary completion 20 September 2027; topline may lag.
Follows the 23 September 2026 advisory committee. PMA decisions typically come months after the panel; no date has been announced.
SourceThe first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population. Timing is our estimate from the registry record; the sponsor has not given a date.
SourcePhase 3 in first-line KRAS G12C-mutant NSCLC. Timing is a registry-based estimate.
SourceThe first phase 3 comparing KRAS G12C inhibitors head to head. Timing is a registry-based estimate.
SourcePivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sankyo collaboration. Timing is a registry-based estimate.
SourcePhase 2/3 for the CDH6 ADC. Timing is a registry-based estimate.
SourceWould move the TROP2 ADC into the first-line EGFR-mutant setting on top of the standard TKI. Timing is a registry-based estimate.
SourceTests the ADC as the first chemotherapy after endocrine therapy. Timing is a registry-based estimate.
SourceThe sponsors said filings would follow the positive topline result of August 2026 and the full data presentation. Timing is our estimate.
SourceMerck holds a Commissioner's National Priority Voucher (July 2026) that promises a 1 to 2 month review once filed. No PDUFA date has been disclosed; indication (TNBC vs EGFR-mutant NSCLC) and filing timing are not public.
SourceEvent-driven iDFS endpoint in patients with residual disease after KEYNOTE-522-type therapy. Would be the first ADC in the curative TNBC setting.
Confirmed events carry a source that states the date: a PDUFA goal date in a sponsor release, an advisory committee notice, a congress programme. Expected events are our estimate from the registry primary completion date and sponsor statements; treat them as a quarter, not a day.
Companies are attached directly for catalysts and derived for readout-calendar rows from the products named (each product’s companies in the corpus). Past events stay in the data and can be shown with the checkbox.
Subscribe to /catalysts/feed.ics in Google Calendar, Outlook or Apple Calendar to get every event, including expected ones placed on the first day of their period. The download button exports only the rows you have filtered to.
Missing a catalyst? Add it to src/data/catalysts.ts with company and product ids and a source; congresses and policy dates belong in src/data/calendar.ts.